Critical Analysis: Chiasma (CHMA) and Sinovac Biotech (SVA)

Chiasma (NASDAQ: CHMA) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.

Profitability

This table compares Chiasma and Sinovac Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chiasma N/A -36.49% -32.48%
Sinovac Biotech N/A N/A N/A

Earnings and Valuation

This table compares Chiasma and Sinovac Biotech’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chiasma $10,000.00 4,510.30 -$61.11 million ($1.17) -1.58
Sinovac Biotech $72.43 million 6.19 -$590,000.00 ($0.01) -785.21

Sinovac Biotech has higher revenue and earnings than Chiasma. Sinovac Biotech is trading at a lower price-to-earnings ratio than Chiasma, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

54.6% of Chiasma shares are owned by institutional investors. Comparatively, 31.8% of Sinovac Biotech shares are owned by institutional investors. 3.8% of Chiasma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Chiasma and Sinovac Biotech, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chiasma 1 0 0 0 1.00
Sinovac Biotech 0 0 0 0 N/A

Summary

Sinovac Biotech beats Chiasma on 5 of the 8 factors compared between the two stocks.

About Chiasma

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

About Sinovac Biotech

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company’s pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply